SCHEMBL21591439

SCHEMBL21591439

Cc1ccc2c(=O)c(CN(CCCn3ccnc3)Cc3ccncc3)coc2c1C

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CYP11B1 P15538 3/20 0.37
▸ CYP11B2 P19099 3/20 0.37
▸ POLB P06746 1/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ ALOX15 P16050 2/20 0.34
▸ LMNA P02545 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ PRKCI P41743 1/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ ATM Q13315 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21591449 0.92 SMN1; SMN2 (0.35) CYP11B1CYP11B2POLBSMN1; SMN2ALDH1A1
SCHEMBL21591532 0.89 CYP11B1 (0.39) CYP11B1CYP11B2POLBSMN1; SMN2ALDH1A1
SCHEMBL21592292 0.88 CYP11B1 (0.40) CYP11B1CYP11B2POLBSMN1; SMN2ALDH1A1
SCHEMBL21591444 0.85 CYP11B1 (0.42) CYP11B1CYP11B2POLBALDH1A1TSHR
SCHEMBL21592244 0.85 SMN1; SMN2 (0.33) CYP11B1CYP11B2SMN1; SMN2ALDH1A1ALOX15
SCHEMBL21591466 0.84 POLB (0.35) CYP11B1CYP11B2POLBALDH1A1ALOX15
SCHEMBL21592275 0.82 CYP11B1 (0.43) CYP11B1CYP11B2HPGDMEN1KMT2A
SCHEMBL21591502 0.81 CYP11B1 (0.59) CYP11B1CYP11B2MEN1KMT2ANPC1
SCHEMBL21591479 0.80 CYP11B1 (0.47) CYP11B1CYP11B2MEN1KMT2ANPC1
SCHEMBL21591489 0.80 CYP11B1 (0.62) CYP11B1CYP11B2HPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3807264-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2021-04-21 — — EP claimed
WO-2019238786-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2019-12-19 — — WO claimed
US-20220402898-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2022-12-22 — — US disclosed
EP-3807264-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2021-04-21 — — EP disclosed
WO-2019238786-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2019-12-19 — — WO disclosed
WO-2019238786-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2019-12-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220402898-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) STING1, IRF3, CGAS CYP11B1 43/4885CYP11B2 50/4885POLB 292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback